Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease
NCT ID: NCT00323258
Last Updated: 2013-01-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
143 participants
INTERVENTIONAL
2006-06-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An mHealth Intervention to Improve Medication Adherence and Health Outcomes
NCT04703439
A Randomized Controlled Trial to Improve Medication Compliance Among Patients With Coronary Heart Disease
NCT00208832
Effect of Patient Education on Compliance and Cardiovascular Risk Parameters
NCT02096887
A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.
NCT00415428
Intervention to Improve Medication Adherence in Cardiovascular Patients
NCT01449695
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Comparisons: Patients admitted to Duke University Hospital or Southeastern Regional Medical Center (SRMC) with CAD or CAD plus heart failure who agree to participate, will be randomized to an intervention or control arm. The control group will receive usual care, which consists of routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the Duke physician to the community physician. In addition to usual care, the intervention group will receive focused medication counseling in the hospital by the clinical pharmacist-investigator, who will identify and address potential barriers to medication adherence and will reinforce the importance of taking evidence-based medications long term. Discharge medications will be shared with the community pharmacist. The community pharmacist will monitor for problems with adherence and communicate issues back to the patient and the patient's care team.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
oral education & written tips for remembering medications
Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
pill box
Subject is provided a pill box and briefly instructed on how to use the box.
pocket medication card
Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
sharing information with community pharmacist
A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
Medication use evaluations by community pharmacist
The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
informing physician if patient has stopped a medication
The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
Routine discharge counseling
Both groups received routine discharge counseling performed by the patient-care nurse.
Letter to physician/discharge summary
A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
Usual Care
The usual care group received routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations. Enrolled patients in the usual care arm were not disclosed to the community pharmacy until the end of the study period when refill records were requested.
Routine discharge counseling
Both groups received routine discharge counseling performed by the patient-care nurse.
Letter to physician/discharge summary
A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oral education & written tips for remembering medications
Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
pill box
Subject is provided a pill box and briefly instructed on how to use the box.
pocket medication card
Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
sharing information with community pharmacist
A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
Medication use evaluations by community pharmacist
The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
informing physician if patient has stopped a medication
The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
Routine discharge counseling
Both groups received routine discharge counseling performed by the patient-care nurse.
Letter to physician/discharge summary
A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Utilize a pharmacy in Durham, Robeson, Person, Granville, or Vance County, NC
* Have coronary artery disease (CAD) documented in the medical record by one of the following:
1. A diagnosis of unstable angina or acute myocardial infarction (ST segment elevation or non-ST segment elevation myocardial infarction)
2. A cardiac catheterization demonstrating CAD greater than or equal to 50 narrowing of artery)
3. Prior angioplasty
4. Prior coronary artery stent
5. Prior coronary artery bypass graft surgery (CABG)
* Plan to have their prescription medications filled and refilled by one of the participating pharmacies
* Prescribed aspirin or another antiplatelet, a beta-blocker and statin agent (referred to as triple therapy for this study) at discharge. If a patient has a true contraindication to any of the three medication groups in triple therapy, they will still be eligible for the study
Exclusion Criteria
* Patient plans to use a pharmacy outside of Durham, Robeson, Person, Granville, or Vance County, NC
* Patient is unable to give consent (cognitively impaired, does not speak English, or has altered mental status)
* Patient transferred to Cardiothoracic Surgery service for CABG
* Patient has terminal condition and may not survive until 6-month follow-up
* Patient lives in a correctional or long-term care facility
* Patient will be unable to participate in follow-up phone call (hearing impaired without caregiver who can help or does not have a phone)
* Patient is a known participant in the Duke Heart Failure Program
* Patient does not agree to use only the one Durham, Robeson, Person, Granville, or Vance County pharmacy throughout the study period
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Agency for Healthcare Research and Quality (AHRQ)
FED
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Judith M. Kramer, MD,MS
Role: PRINCIPAL_INVESTIGATOR
Duke University
Nancy Allen LaPointe, PharmD
Role: PRINCIPAL_INVESTIGATOR
Duke University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Medical Center
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006 Jan 17;113(2):203-12. doi: 10.1161/CIRCULATIONAHA.105.505636. Epub 2006 Jan 9.
Calvert SB, Kramer JM, Anstrom KJ, Kaltenbach LA, Stafford JA, Allen LaPointe NM. Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J. 2012 Apr;163(4):657-65.e1. doi: 10.1016/j.ahj.2012.01.019.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00005018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.